-
公开(公告)号:ES2351208T3
公开(公告)日:2011-02-01
申请号:ES02800666
申请日:2002-10-10
Applicant: UCB PHARMA SA
Inventor: POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , MORRISON ROBERT KENDALL , ZINKEWICH-PEOTTI KAREN
IPC: C07K16/28 , C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08
Abstract: Una molécula de anticuerpo que tiene especificidad para KDR humano, que comprende una región variable de la cadena pesada del SEQ ID NO: 15 y una región variable de la cadena ligera del SEQ ID NO: 16.
-
公开(公告)号:UY32451A
公开(公告)日:2010-09-30
申请号:UY32451
申请日:2010-02-17
Applicant: UCB PHARMA SA
Inventor: LAWSON ALASTAIR DAVID GRIFFITHS , NESBITT ANDREW MALCOLM , POPPLEWELL ANDREW GEORGE , SHAW STEPHEN GRAHAM , DIANA SHPEKTOR , YI ZHANG
IPC: A61K39/00 , A61K39/395 , A61K39/44 , A61P37/00 , C07K16/28 , C12N1/21 , C12N15/09 , C12N15/13 , C12N15/70
Abstract: La invención se refiere a moléculas de anticuerpo con especifícidad por los determinantes antigénicos del 0X40 humano, usos terapéuticos de las moléculas de anticuerpo, y métodos para producir moléculas de anticuerpo
-
公开(公告)号:CA2751477A1
公开(公告)日:2010-08-26
申请号:CA2751477
申请日:2010-02-17
Applicant: UCB PHARMA SA
Inventor: LAWSON ALASTAIR DAVID GRIFFITHS , NESBITT ANDREW MALCOLM , POPPLEWELL ANDREW GEORGE , SHAW STEVAN GRAHAM , SHPEKTOR DIANA , ZHANG YI
IPC: C07K16/28 , A61K39/395 , A61P37/06 , C07K14/705 , C07K17/08 , C12N15/13
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号:DE60140738D1
公开(公告)日:2010-01-21
申请号:DE60140738
申请日:2001-06-05
Applicant: UCB PHARMA SA
Inventor: ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , C12N15/13 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C07K19/00 , C12N1/21 , C12N15/62 , C12N15/70 , C12P21/02 , C12P21/08
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF± There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF±
-
公开(公告)号:ECSP099683A
公开(公告)日:2009-12-28
申请号:ECSP099683
申请日:2009-10-08
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor: POPPLEWELL ANDREW GEORGE , BROWN DEREK THOMAS , ADAMS RALPH , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Abstract: Esta invención proporciona proteínas de unión, que incluyen anticuerpos, derivados de anticuerpo, y fragmentos de anticuerpo, que específicamente se unen a la proteína CD154 (CD40L). Esta invención también proporciona un anticuerpo quimérico, humanizado o completamente humano, derivado de anticuerpo o fragmento de anticuerpo que específicamente se une a un epítopo al cual se une un fragmento Fab humanizado que comprende una secuencia de cadena pesada variable de acuerdo con SEC ID NO: 1 y comprende una secuencia de cadena ligera variable de acuerdo con SEC ID NO: 2. Las proteínas de unión CD154 de esta invención pueden producir una función efectora reducida con relación a un segundo anticuerpo anti-CD154. Las proteínas de unión CD154 de la invención son útiles en métodos de diagnóstico y terapéuticos, tales como en el tratamiento y prevención de enfermedades que incluyen las que involucran respuestas inmunitarias indeseables que están mediadas por las interacciones de CD154-CD40
-
公开(公告)号:AU2003223007B2
公开(公告)日:2009-07-16
申请号:AU2003223007
申请日:2003-05-02
Applicant: UCB PHARMA SA
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
公开(公告)号:NO20083066L
公开(公告)日:2008-09-08
申请号:NO20083066
申请日:2008-07-08
Applicant: UCB PHARMA SA
Inventor: GELINAS RICHARD EVAN , SINGHAL MITRA CHOUDHURY , ZHANG YI , POPPLEWELL ANDREW GEORGE , ADAMS RALPH
IPC: C07K16/24 , A61K39/395 , C07K16/18
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号:CA2655874A1
公开(公告)日:2008-01-03
申请号:CA2655874
申请日:2007-06-25
Applicant: UCB PHARMA SA
Inventor: POPPLEWELL ANDREW GEORGE , ADAMS RALPH , RAPECKI STEPHEN EDWARD
IPC: C07K16/24 , A61K39/395 , C12N5/20 , C12N15/13
Abstract: The invention relates to antibody molecules having specificity for antige nic determinants of IL-17, therapeutic uses of the antibody molecules and me thods for producing said antibody molecules.
-
公开(公告)号:CA2632628A1
公开(公告)日:2007-06-14
申请号:CA2632628
申请日:2006-12-04
Applicant: UCB PHARMA SA
Inventor: POPPLEWELL ANDREW GEORGE , ZHANG YI , ADAMS RALPH , GELINAS RICHARD EVAN , SINGHAL MITRA CHOUDHURY
IPC: C07K16/24
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号:AU2005305677A1
公开(公告)日:2006-05-26
申请号:AU2005305677
申请日:2005-11-16
Applicant: UCB PHARMA SA
Inventor: ADAMS RALPH , RAPECKI STEPHEN EDWARD , TICKLE SIMON PETER , POPPLEWELL ANDREW GEORGE
Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
-
-
-
-
-
-
-
-
-